- Home
- BAK vs EWTX Comparison
BAK vs EWTX Comparison
Compare BAK & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAK
- EWTX
- Stock Information
- Founded
- BAK 1972
- EWTX 2017
- Country
- BAK Brazil
- EWTX United States
- Employees
- BAK N/A
- EWTX N/A
- Industry
- BAK Major Chemicals
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- BAK Industrials
- EWTX Health Care
- Exchange
- BAK Nasdaq
- EWTX Nasdaq
- Market Cap
- BAK 1.4B
- EWTX 1.2B
- IPO Year
- BAK N/A
- EWTX 2021
- Fundamental
- Price
- BAK $3.56
- EWTX $14.30
- Analyst Decision
- BAK Strong Buy
- EWTX Buy
- Analyst Count
- BAK 3
- EWTX 8
- Target Price
- BAK $9.75
- EWTX $39.63
- AVG Volume (30 Days)
- BAK 1.1M
- EWTX 954.4K
- Earning Date
- BAK 08-06-2025
- EWTX 08-07-2025
- Dividend Yield
- BAK N/A
- EWTX N/A
- EPS Growth
- BAK N/A
- EWTX N/A
- EPS
- BAK N/A
- EWTX N/A
- Revenue
- BAK $13,770,122,923.00
- EWTX N/A
- Revenue This Year
- BAK $18.11
- EWTX N/A
- Revenue Next Year
- BAK $7.32
- EWTX N/A
- P/E Ratio
- BAK N/A
- EWTX N/A
- Revenue Growth
- BAK 14.35
- EWTX N/A
- 52 Week Low
- BAK $2.85
- EWTX $10.60
- 52 Week High
- BAK $7.71
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- BAK 45.20
- EWTX 41.90
- Support Level
- BAK $3.62
- EWTX $14.87
- Resistance Level
- BAK $3.87
- EWTX $15.68
- Average True Range (ATR)
- BAK 0.13
- EWTX 0.67
- MACD
- BAK -0.02
- EWTX -0.02
- Stochastic Oscillator
- BAK 11.46
- EWTX 15.25
About BAK Braskem SA ADR
Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.